<a href="https://www.fiercebiotech.com/biotech/lilly-continues-ma-streak-23b-deal-next-gen-jak-inhibitor-biotech-ajax" hreflang="en">Lilly maintains M&A hot streak with $2.3B deal for next-gen JAK inhibitor biotech Ajax</a>
Eli Lilly has continued its acquisition spree by purchasing Ajax Therapeutics for $2.3 billion to advance its clinical-stage JAK2 inhibitor, AJ1-11095, aimed at treating myelofibrosis. The drug is expected to offer deeper efficacy and a new treatment option for patients resistant to existing therapies.
Eli Lilly's acquisition of Ajax Therapeutics, centered around an innovative Type II JAK2 inhibitor for myelofibrosis, underscores the potential market shift towards more effective treatments for patients resistant to current Type I JAK2 inhibitors. This move not only highlights the value of targeting novel pathways in drug development but also suggests a strategic investment opportunity in companies advancing next-generation therapeutics for unmet needs in hematological malignancies.